Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel

Prostate Cancer and Prostatic Diseases

Volumn 18, Issue 2, 2015, Pages 122-127

  Cheng, H H ^a,b   Gulati, R ^b   Azad, A ^c   Nadal, R ^d   Twardowski, P ^e   Vaishampayan, U N ^f   Agarwal, N ^g   Heath, E I ^f   Pal, S K ^e   Rehman, H T ^d   Leiter, A ^h   Batten, J A ^g   Montgomery, R B ^a,b   Galsky, M D ^h   Antonarakis, E S ^d   Chi, K N ^c   Yu, E Y ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^f WAYNE STATE UNIVERSITY   (United States)

^g UNIVERSITY OF UTAH   (United States)

^h MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; DOCETAXEL; ENZALUTAMIDE; PROSTATE SPECIFIC ANTIGEN; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; PHENYLTHIOHYDANTOIN; TAXOID;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; DRUG WITHDRAWAL; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ANALOGS AND DERIVATIVES; DISEASE FREE SURVIVAL; METASTASIS; MIDDLE AGED; PATHOLOGY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANDROSTENES; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PHENYLTHIOHYDANTOIN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RETROSPECTIVE STUDIES; TAXOIDS; TREATMENT OUTCOME;

EID: 84929277295     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2014.53     Document Type: Article

References (29)

1. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L et al. Abiraterone and increased survival in metastatic prostate cancer. New Engl J Med 2011; 364: 1995-2005.
2. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. New Engl J Med 2012; 367: 1187-1197.
3. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. New Engl J Med 2013; 368: 138-148.
4. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS et al. Enzalutamide in metastatic prostate cancer before chemotherapy. New Engl J Med 2014; 371: 424-433.
5. Bianchini D, Lorente D, Rodriguez-Vida A, Omlin A, Pezaro C, Ferraldeschi R et al. Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone. Eur J Cancer 2014; 50: 78-84.
6. Badrising S, van der Noort V, van Oort IM, van den Berg HP, Los M, Hamberg P et al. Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment. Cancer 2013; 120: 968-975.
7. Thomson D, Charnley N, Parikh O. Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate-resistant prostate cancer. Eur J Cancer 2014; 50: 1040-1041.
8. Schmid SC, Geith A, Boker A, Tauber R, Seitz AK, Kuczyk M et al. Enzalutamide after docetaxel and abiraterone therapy in metastatic castration-resistant prostate cancer. Adv Ther 2014; 31: 234-241.
9. Azad AA, Eigl BJ, Murray RN, Kollmannsberger C, Chi KN. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castrationresistant prostate cancer patients. Eur Urol 2014; 67: 23-29.
10. Ileana E, Loriot Y, Albiges L, Massard C, Blesius A, Di Palma M et al. Abiraterone in patients with metastatic castration-resistant prostate cancer progressing after docetaxel and MDV3100. J Clin Oncology; (Meeting Abstracts) 2012 vol 30 no.15-suppl 4554.
11. Loriot Y, Bianchini D, Ileana E, Sandhu S, Patrikidou A, Pezaro C et al. Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol 2013; 24: 1807-1812.
12. Noonan KL, North S, Bitting RL, Armstrong AJ, Ellard SL, Chi KN. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol 2013; 24: 1802-1807.
13. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 1148-1159.
14. Chi KN, San Kheoh T, Ryan CJ, Molina A, Bellmunt J, Vogelzang NJ et al. A prognostic model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel. J Clin Oncol; (Meeting Abstracts) 2013 vol 31 no 15-suppl 5013
15. Halabi S, Lin CY, Kelly WK, Fizazi KS, Moul JW, Kaplan EB et al. Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2014; 32: 671-677.
16. Armstrong AJ, Tannock IF, de Wit R, George DJ, Eisenberger M, Halabi S. The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. Eur J Cancer 2010; 46: 517-525.
17. Schrader AJ, Boegemann M, Ohlmann CH, Schnoeller TJ, Krabbe LM, Hajili T et al. Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. Eur Urol 2014; 65: 30-36.
18. Armstrong AJ, Garrett-Mayer ES, Yang YC, de Wit R, Tannock IF, Eisenberger M. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res 2007; 13: 6396-6403.
19. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008; 68: 4447-4454.
20. Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 2013; 155: 1309-1322.
21. Mostaghel EA, Marck BT, Plymate SR, Vessella RL, Balk S, Matsumoto AM et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res 2011; 17: 5913-5925.
22. Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, Dehm SM. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res 2013; 73: 483-489.
23. Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, Tannahill C et al. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res 2012; 72: 3457-3462.
24. Korpal M, Korn JM, Gao X, Rakiec DP, Ruddy DA, Doshi S et al. An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). Cancer Discovery 2013; 3: 1030-1043.
25. Schweizer MT, Zhou XC, Wang H, Bassi S, Carducci MA, Eisenberger MA et al. The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer. Eur Urol 2014; 66: 646-652.
26. van Soest RJ, van Royen ME, de Morree ES, Moll JM, Teubel W, Wiemer EA et al. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. Eur J Cancer 2013; 49: 3821-3830.
27. Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 2011; 19: 575-586.
28. Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. New Engl J Med 2014; 371: 1028-1038.
29. Azad A, Volik S, Wyatt A, Haegert A, Collins C, Chi KN. Genomic analysis of circulating tumor DNA in plasma of metastatic castration-resistant prostate cancer patients treated with abiraterone acetate and enzalutamide. J Clin Oncol 2014; 32: 5s.